Can a smart drug missile take down a tough ovarian cancer?
NCT ID NCT07718854
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The study enrolls about 50 adults with this rare cancer type. The main goal is to see how many patients respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan, an antibody-drug conjugate targeting Trop-2, given alone or combined with pembrolizumab, an immunotherapy drug
- What this could lead to
- If effective, this combination could offer a new treatment option for a rare and aggressive ovarian cancer that has stopped responding to immunotherapy.
- What could go wrong
- This is a small, early-phase trial, so results may not apply broadly. Antibody-drug conjugates and immunotherapies can cause serious side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill aims to shrink Hard-to-Treat cancers
- New drug duo aims to outperform chemo in rare ovarian cancer
- Pazopanib dose hunt in frail seniors halted early
- New vaccine combo shows promise in ovarian cancer fight
- New targeted drug shows promise for Hard-to-Treat gynecologic cancers
- Experimental antibody combo shows promise against tough cancers